Effects of batroxobin combined with dual antiplatelet therapy in the treatment of acute cerebral infarction
Objective To observe the clinical efficacy of batroxobin combined with dual antiplatelet therapy in the treatment of acute cerebral infarction.Methods 98 patients with acute cerebral infarction were randomly divided into the dual group and batroxobin group using the random number table method,with 49 cases in each group.The dual group were received dual antiplatelet therapy,while the batroxobin group were received a combination of batroxobin and dual antiplatelet therapy.The platelet activity,fibrinolytic system function,vascular endothelial function,cerebral blood flow,and adverse prognosis were compared between two groups of patients.Results Under different treatment regimens,the levels of platelet aggregation(PAgT),platelet adhesion in Patroase(PAdT),D-dimer(D-D)and fibrinogen(FIB)in the batroxobin group were lower than those in the dual group,and the difference was statistically significant(P<0.05).The levels of plasminogen activation inhibitor(PAI-1),tissue plasminogen activator(t-PA),and endothelin-1(ET-1)in the batroxobin group were lower than those in the dual group,while NO was higher in the dual group(P<0.05).The plasma viscosity,high shear viscosity,low shear viscosity,and low perfusion index(HIR)in the batroxobin group were all lower than those in the duplex group(P<0.05).The incidence of poor prognosis in the batroxobin group was 4.08%(2/49)lower than that in the dual group of 20.41%(10/49)(P<0.05).Conclusion The combination of batroxobin and dual antiplatelet therapy can promote vascular endothelial function and cerebral blood flow in patients with acute cerebral infarction by inhibiting platelet activity and improving fibrinolytic system function,which has a positive significance in reducing the risk of adverse prognosis.
acute cerebral infarctionbatroxobindual antiplatelet therapyplatelet activityfibrinolysis system function
万方数据
维普
